Heart failure with preserved ejection fraction (HFpEF) affects nearly half of all heart failure patients, yet its treatment has long lagged behind other forms. Recent updates from leading organizations like the American Heart Association and the European Society of Cardiology now offer clearer guidance. In this article, we'll break down the key recommendations for HFpEF management and how they can help you or a loved one.

Understanding HFpEF and the Need for Guidelines

HFpEF occurs when the heart's left ventricle stiffens and cannot relax properly, leading to fluid buildup and symptoms like shortness of breath and fatigue. For years, treatment options were limited, but recent clinical trials have changed the landscape. The 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure now provides specific recommendations for HFpEF. These guidelines are essential because they standardize care, helping clinicians identify optimal therapies and improve patient outcomes.

Key Recommendations for HFpEF Management

The latest HFpEF clinical practice guidelines emphasize a multifaceted approach. Here are the core recommendations:

  • Diuretics to manage congestion and improve symptoms.
  • SGLT2 inhibitors (e.g., empagliflozin) now have a Class 1 recommendation based on the EMPEROR-Preserved trial.
  • Treatment of comorbidities such as hypertension, atrial fibrillation, and obesity.
  • Structured exercise training to improve functional capacity.

These recommendations represent a shift from purely symptom management to disease-modifying therapy. According to the 2021 ESC Guidelines, SGLT2 inhibitors are now the cornerstone of HFpEF treatment.

The Role of SGLT2 Inhibitors in HFpEF

SGLT2 inhibitors, originally developed for diabetes, have emerged as a breakthrough for HFpEF. The EMPEROR-Preserved trial, published in the New England Journal of Medicine, showed that empagliflozin reduced the risk of cardiovascular death or hospitalization for heart failure by 21% in HFpEF patients. These benefits are consistent regardless of diabetes status, making SGLT2 inhibitors a key part of HFpEF treatment guidelines clinical practice now recommends. For individuals with HFpEF, this means a powerful new tool to improve quality of life and reduce hospital visits.

Lifestyle Modifications and Monitoring

Beyond medications, heart failure preserved ejection fraction management involves lifestyle changes. The guidelines recommend a heart-healthy diet low in sodium, regular physical activity as tolerated, and weight management for obese patients. Daily monitoring of weight and symptoms can help detect fluid retention early. According to the CDC, self-care practices like these are crucial for preventing exacerbations. Your healthcare team can tailor a plan that fits your needs—consult a professional before starting any new regimen.

Staying up to date with HFpEF clinical practice guidelines empowers both patients and clinicians to make informed decisions. With new treatments like SGLT2 inhibitors and a focus on holistic care, managing HFpEF has never been more promising. If you or someone you know has heart failure with preserved ejection fraction, consider exploring these recommendations further. A conversation with your doctor can help personalize these guidelines to your unique health journey.